Dermatitis News

Researchers were unable to identify the most effective antibiotic treatment for cellulitis, as no one antibiotic was superior over another based on available clinical trial data, according to researchers in JAMA Dermatology.

In a study investigating the relationship between hidradenitis suppurativa and alopecia areata in a U.S. sample, those with hidradenitis suppurativa had a significantly higher risk for alopecia of any type and also lichen planopilaris.

“The possibility of being able to educate patients with something ‘concrete’ that they can see and touch could be a great addition to patient education,” Noelani González, MD, clinical instructor of dermatology at Mount Sinai Hospital, told Healio Dermatology regarding a recent popular story on research using a 3D-printed model before Mohs micrographic surgery.

Patients with moderate to severe psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study data presented at the World Congress of Dermatology in Milan.

Depression and anxiety may be common in patients with hidradenitis suppurativa, although researchers were unable to prove a causal relationship, according to a study in JAMA Dermatology.

Baricitinib significantly improved the signs and symptoms of moderate to severe atopic dermatitis compared with placebo, according to results from two phase 3 studies, BREEZE-AD1 and BREEZE-AD2, presented at the World Congress of Dermatology.

Patients with moderatetosevere psoriasis treated with ixekizumab showed high rates of improvement and no unexpected safety outcomes for up to 5 years of treatment, according to study results presented at World Congress of Dermatology in Milan.

Patients with central obesity, insulin resistance and active psoriasis are at high risk for liver fibrosis, according to researchers from King’s College London.

Most patients with moderate to severe plaque psoriasis who received treatment with brodalumab experienced long-term rates of skin clearance at 120 weeks, according to extension results of AMAGINE-2.

IFX-1, a monoclonal anti-human complement factor C5a antibody, showed no significant dose response in patients with hidradenitis at week 16 of the SHINE phase 2b study, in the top Healio Dermatology story from last week.